A Prospective Randomised Clinical Trial Evaluating Pulpotomy in Primary Molars With Three Bioceramic Calcium Silicate Cements: 24 Month Follow‐Up
International Journal of Paediatric Dentistry · 2025-07 · 35 (4) · 763-773
DOI: 10.1111/ipd.13288 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Paediatric Dentistry, online erschienen am 06.12.2024. Verfasst von Abhinav L Talekar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pedodontics and Preventive Dentistry, M.A. Rangoonwala College of Dental Sciences and Research Centre, Pune, Maharashtra, India. Hauptthemen laut MEDLINE: Calcium Compounds, Silicates, Pulpotomy, Tooth, Deciduous. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
In recent times, bioceramic calcium silicates have gained attention due to high success rates with pulpotomy in primary teeth.
Aims
To evaluate and compare the clinical and radiographic outcomes of three different bioceramic calcium silicate cements in vital deciduous teeth treated with pulpotomies over a period of 24 months.
Design
Children aged 4–9 years, with deep dentinal caries (ICDAS 4–6) in primary molars, having no history of spontaneous pain or signs of non‐vitality were included in the study. Following clinical and radiographic evaluation 117 primary molars diagnosed as having reversible pulpitis received pulpotomy treatment, after randomly being assigned into three groups based on the bioceramic calcium silicate medicament used: a pre‐mixed syringe‐loaded MTA putty (NeoPUTTY); a traditional powder‐liquid hand mix MTA material (NeoMTA Plus), and a precapsulated, trituration mixed material (Biodentine). Clinical and radiographic evaluation was done at 6, 12, 18 and 24 months.
Results
The cumulative clinical and radiographic success for NeoPUTTY was 92%, NeoMTA Plus 97% and for Biodentine 95% and 89%, respectively, after 24 months follow‐up.
Conclusion
The clinical and radiographic success rates of all three bioceramic calcium silicate cements were found to be high, with no significant differences over a period of 24 months. Trial Registration Clinical trial registration number: CTRI/2021/03/031655
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pedodontics and Preventive Dentistry, M.A. Rangoonwala College of Dental Sciences and Research Centre, Pune, Maharashtra, India.
- Private Practitioner at Kids Dental Corner Camp, Pune, Maharashtra, India.
- SMBT Institute of Dental Science and Research, Nasik, Maharashtra, India.
- Department of Pedodontics and Preventive Dentistry, Private Practitioner at Little Ones Big Smiles, Pune, Maharashtra, India.
- G. D. Pol Foundation's YMT Dental College, Navi Mumbai, Maharashtra, India.
- Private Practitioner at Pediatric Dental Care Associates, Las Vegas, Nevada, USA.
ORCID-Profile: Abhinav L Talekar, Prasad K Musale, Tayaba M H Silotry
Zitieren
APA
Talekar, A. L., Musale, P. K., Chaudhari, G. S., Silotry, T. M. H., & Waggoner, W. F. (2025). A Prospective Randomised Clinical Trial Evaluating Pulpotomy in Primary Molars With Three Bioceramic Calcium Silicate Cements: 24 Month Follow‐Up. International Journal of Paediatric Dentistry, 35(4), 763-773. https://doi.org/10.1111/ipd.13288
Vancouver
Talekar AL, Musale PK, Chaudhari GS, Silotry TMH, Waggoner WF. A Prospective Randomised Clinical Trial Evaluating Pulpotomy in Primary Molars With Three Bioceramic Calcium Silicate Cements: 24 Month Follow‐Up. International Journal of Paediatric Dentistry. 2025;35(4):763-773. doi:10.1111/ipd.13288
BibTeX
@article{Talekar2025,
author = {Talekar, Abhinav L and Musale, Prasad K and Chaudhari, Gayatri S and Silotry, Tayaba M H and Waggoner, William F},
title = {A Prospective Randomised Clinical Trial Evaluating Pulpotomy in Primary Molars With Three Bioceramic Calcium Silicate Cements: 24 Month Follow‐Up},
journal = {International Journal of Paediatric Dentistry},
year = {2025},
volume = {35},
number = {4},
pages = {763--773},
doi = {10.1111/ipd.13288}
}
EUVIMED